Ibogaine is currently unscheduled under Senegalese national law, meaning it is neither explicitly prohibited nor formally regulated as a controlled substance. Last verified: April 22, 2026.

Current Legal Status

Senegal does not list ibogaine or iboga alkaloids on any national controlled substances schedule. The country's primary drug control framework is governed by Law No. 97-18 of 1997 on Narcotic Drugs and Psychotropic Substances, which aligns broadly with Senegal's obligations under the 1971 UN Convention on Psychotropic Substances. Ibogaine does not appear on the schedules of that Convention, and Senegal has not independently added it to domestic scheduling lists.

Iboga (Tabernanthe iboga) is native to the broader Central and West African region, and while it is more historically central to Gabon and the Bwiti tradition of Central Africa, its use has cultural and ceremonial relevance in parts of Senegal as well. No specific legislation restricts the possession, cultivation, or use of iboga plants or ibogaine-containing preparations for religious or traditional purposes in Senegal.

The Ordre National des Pharmaciens du Sénégal (National Order of Pharmacists of Senegal) oversees pharmaceutical regulation, but ibogaine has not been submitted for drug approval and is not available through licensed pharmacies. Its unscheduled status means legal ambiguity rather than explicit permission: there is no affirmative framework authorizing its clinical use either.

Religious and Traditional Carve-Outs: Senegalese law does not contain explicit carve-outs for iboga or ibogaine in religious contexts. However, traditional and indigenous medicine practices are broadly tolerated, and enforcement action against ceremonial iboga use is not documented in Senegalese legal records.

Treatment Centers

Formal ibogaine treatment centers operating under Western clinical protocols are not currently established in Senegal. The country does not have a regulatory framework that would license or accredit ibogaine clinics in the manner seen in Mexico or Portugal. However, Senegal's proximity to Gabon — the global center of Bwiti iboga ceremony — means that traditional ceremonial contexts exist across the region and informal access points may be present.

No ibogaine clinics in Senegal are currently listed in major international treatment directories. If you are researching ibogaine treatment providers globally, visit our full clinic directory for vetted options in countries with established treatment infrastructure.

How People Access Ibogaine in Senegal

Access to ibogaine in Senegal, where it occurs, takes place through the following channels — described here factually and without recommendation:

  • Traditional and ceremonial contexts: Some individuals engage with iboga through West and Central African traditional healers or through connections to Bwiti-adjacent practices. These ceremonies are not regulated by the state and vary enormously in structure, setting, and safety protocols.
  • Travel to Gabon: Senegalese nationals and visitors interested in iboga ceremonies sometimes travel to Gabon, where the Bwiti tradition is legally recognized and the plant is considered a national heritage substance.
  • Informal sourcing: Because ibogaine is unscheduled, iboga root bark or ibogaine preparations are not subject to controlled-substance import/export enforcement under Senegalese law, though international trafficking laws and the laws of the country of origin would still apply.
  • International clinical travel: Individuals seeking medically supervised ibogaine treatment — particularly for opioid use disorder — typically travel to established clinics in Mexico, Portugal, or other countries with operational treatment centers.

Recent Legal Developments

Within the past two years, no legislation specifically addressing ibogaine or iboga alkaloids has been introduced or passed in the Senegalese National Assembly. Senegal has not moved to schedule or restrict ibogaine, nor has it taken steps toward a formal clinical or therapeutic framework.

Regionally, growing global attention to ibogaine's potential in treating opioid use disorder — including a landmark study published in Nature Medicine in 2023 examining ibogaine and TBI — has prompted policy conversations in North America and Europe. These discussions have not yet translated into formal regulatory action in Senegal.

Senegal's broader drug policy reform discussions have focused primarily on cannabis, following regional trends in West Africa, rather than on psychedelic or entheogenic substances such as ibogaine.

Important: The absence of scheduling does not mean ibogaine use is actively sanctioned by Senegalese health authorities. No clinical safety standards, approved providers, or emergency protocols specific to ibogaine exist within the country's formal healthcare system.

Risks of Seeking Treatment in Senegal

For individuals considering ibogaine use in Senegal, the following risk factors are relevant and should be carefully considered:

  • No medical oversight standards: Senegal has no regulations governing ibogaine administration, meaning providers — ceremonial or otherwise — are not required to conduct cardiac screening, obtain medical history, or manage contraindications. Ibogaine carries a known risk of fatal cardiac arrhythmia, particularly QTc prolongation, in individuals with underlying heart conditions.
  • No quality control: Iboga preparations sourced outside licensed pharmaceutical supply chains may be of unknown concentration and purity. Dosing errors are a documented cause of ibogaine-related fatalities globally.
  • Limited emergency medical infrastructure: While Senegal has healthcare facilities in Dakar and major cities, emergency cardiac care resources outside urban centers are limited. In the event of a medical emergency during an ibogaine experience — which can last 24–36 hours — rapid access to advanced cardiac life support may not be available.
  • Unvetted practitioners: In the absence of a licensing framework, there is no way to verify the training, experience, or credentials of anyone offering ibogaine or iboga ceremonies in Senegal.
  • Ceremonial vs. clinical contexts: Traditional Bwiti-style ceremonies are designed with spiritual and initiatory goals, not addiction medicine or mental health treatment outcomes. Conflating these contexts can lead to unmet expectations and inadequate aftercare.
  • Drug interaction risks: Ibogaine has dangerous interactions with many substances, including opioids, stimulants, SSRIs, and lithium. Without medical screening, these interactions may go undetected.

Frequently Asked Questions

Ibogaine is currently unscheduled in Senegal, meaning it does not appear on the country's controlled substances lists under Law No. 97-18 of 1997. It is neither explicitly legal nor explicitly prohibited. However, it also lacks any approved clinical or medical status, so it exists in a legal gray zone. This could change if Senegal updates its drug scheduling lists in response to international developments.
Because ibogaine is not scheduled in Senegal, its importation is not specifically prohibited under Senegalese drug law. However, the laws of the country you are departing from are equally relevant — ibogaine is a Schedule I controlled substance in the United States, for example, making export from the US a federal offense regardless of the destination country's laws. Always verify the laws of both your country of origin and Senegal before transporting any substance internationally. This is not legal advice.
No. There are currently no licensed ibogaine treatment clinics operating in Senegal under a formal regulatory framework. Senegal does not have a clinical licensing pathway for ibogaine providers. If you are seeking medically supervised ibogaine treatment, visit our clinic directory for countries with established and vetted ibogaine treatment infrastructure.
Iboga is most deeply embedded in the Bwiti tradition of Gabon and parts of Cameroon and the Republic of the Congo. While Senegal is geographically and culturally part of West Africa, the Bwiti tradition is primarily a Central African practice. Some exposure to iboga exists in Senegal through cultural exchange and proximity, but it does not hold the same foundational religious role as it does in Gabon, where it is recognized as a national intangible heritage. No specific law in Senegal recognizes or protects iboga religious use.
Countries with the most developed medically supervised ibogaine treatment infrastructure currently include Mexico, Portugal, and South Africa, among others. These jurisdictions have operational clinics with varying levels of medical oversight, pre-treatment cardiac screening protocols, and aftercare support. Our clinic directory provides detailed information on vetted providers. Regardless of location, thorough cardiac screening (including a 12-lead ECG and QTc assessment) is considered essential before ibogaine administration.
It is possible, though no such legislation is currently pending. If the UN Commission on Narcotic Drugs were to add ibogaine to a schedule under the 1971 Convention on Psychotropic Substances — which it has not done — Senegal as a signatory would be expected to implement corresponding domestic controls. Conversely, growing international interest in ibogaine as a therapeutic tool could prompt Senegal to develop a regulated clinical framework rather than a prohibition model. The current trajectory does not suggest imminent scheduling.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.